NEJM This Week — April 2, 2026

This week, we present new research on treatment for muscle-invasive bladder cancer, left atrial appendage closure versus medical therapy for atrial fibrillation, gene-editing approaches for sickle cell disease and β-thalassemia, and the safety of discontinuing beta-blockers after myocardial infarction. We also review GLP-1 receptor agonists and discuss a Clinical Problem-Solving case of a man with progressive confusion. Perspectives explore corporatization; biologic, as opposed to chronologic, aging; and a legal case that could affect mental-health policy.